Jan 15 2021 This Week in Cardiology Jan 15 2021 This Week in Cardiology
COVID, ACE/ARBs, left atrial appendage closure, SGLT2 inhibitors, and a clue in AF mechanisms are the topics discussed by John Mandrola, MD, in this week ’s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 15, 2021 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Biomarker HF Risk Score in Diabetes Seen as SGLT2i Lodestar Biomarker HF Risk Score in Diabetes Seen as SGLT2i Lodestar
Together, 4'easily measured'biomarkers predicted 5-year heart failure risk in patients with diabetes or prediabetes, potentially identifying best candidates for SGLT2 inhibitor therapy, some say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 14, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Euglycemic DKA ID ’ d in T2DM Patients With COVID - 19
Five cases of euDKA identified in patients with type 2 diabetes using SGLT2 inhibitors who developed SARS - CoV - 2 infection (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 5, 2021 Category: Respiratory Medicine Tags: Endocrinology, Family Medicine, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nephrology, Nursing, Pharmacy, Pulmonology, Journal, Source Type: news

Top Cardiology Trials of 2020 in Review Top Cardiology Trials of 2020 in Review
The annual tradition continues as did cardiology research despite a pandemic. Trials on fish oils, statins, SGLT2 inhibitors, and antiplatelets are among the selections of Drs Harrington and Gibson.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 15, 2020 Category: Cardiology Tags: Cardiology Expert Interview Source Type: news

New CREDENCE Data Support SGLT2 Inhibitor Use in Advanced CKD New CREDENCE Data Support SGLT2 Inhibitor Use in Advanced CKD
' We would not recommend initiating treatment with SGLT2 inhibitor in eGFR (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Canagliflozin Beneficial Even for Advanced Kidney Disease
MONDAY, Nov. 30, 2020 -- Treatment with the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduces the rate of kidney disease progression among participants with an estimated glomerular filtration rate (eGRF)
Source: Drugs.com - Pharma News - November 30, 2020 Category: Pharmaceuticals Source Type: news

Regression of LV Hypertrophy With SGLT2 Inhibitors Regression of LV Hypertrophy With SGLT2 Inhibitors
A new study investigates the potential beneficial effects of SGLT2 inhibitors on left ventricular hypertrophy in patients with T2DM. What might be the mechanisms underlying these effects?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
(American Heart Association) Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.Researchers say the results of this randomized clinical trial provide evidence that SGLT2 inhibitors should be part of the standard of care for people with Type 2 diabetes and chronic kidney disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2020 Category: International Medicine & Public Health Source Type: news

SCORED and SOLOIST Trials Add to Evidence for Treating Diabetes with SGLT2 Inhibitors
• SCORED trial of patients with diabetes and chronic kidney disease is first trial of an SGLT2 inhibitor to show benefit across the full range of albuminuria • SOLOIST is the first trial to show an SGLT2 inhibitor is safe to start in patients hospit (Source: BWH News)
Source: BWH News - November 16, 2020 Category: Hospital Management Source Type: news

SCORED and SOLOIST trials add to evidence for treating diabetes with SGLT2 inhibitors
(Brigham and Women's Hospital) In these two paired trials, teams of investigators led by Brigham cardiologist Deepak L. Bhatt, MD, MPH, evaluated sotagliflozin, a drug that inhibits SGLT2 and SGLT1. Results of the trials are both published in The New England Journal of Medicine and presented by Bhatt simultaneously at the Late-Breaking Clinical Trial Sessions of the American Heart Association Scientific Sessions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 16, 2020 Category: International Medicine & Public Health Source Type: news

Empagliflozin Favorably Reshaped LVs in HFrEF Patients Empagliflozin Favorably Reshaped LVs in HFrEF Patients
Treatment with the SGLT2 inhibitor empagliflozin led to significant reductions in both left ventricular end systolic and diastolic volumes in two independent randomized studies of patients with heart failure with reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Adverse Events of High- vs Low-Dose SGLT2 Inhibitors in T2D Adverse Events of High- vs Low-Dose SGLT2 Inhibitors in T2D
SGLT2 inhibitors are commonly used in the treatment of type 2 diabetes, but they are not without side effects. Are the adverse events associated with these agents dose-related?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Benefits of SGLT2 Inhibitors Seen Across Patient Subgroups Benefits of SGLT2 Inhibitors Seen Across Patient Subgroups
The benefits of SGLT2 inhibitors are seen in patients with heart failure and in those with chronic kidney disease, data from two pivotal trials, EMPEROR-Reduced and DAPA-CKD, show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 30, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

ESC 2020 Highlights: Drugs Old and New ESC 2020 Highlights: Drugs Old and New
Top trials from the virtual ESC 2020 featured old drugs such as aspirin and colchicine as well as the new SGLT2 inhibitors.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 12, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news

October 9 2020 This Week in Cardiology October 9 2020 This Week in Cardiology
COVID-19, scientific philosophy, left main coronary artery disease, empagliflozin and the SGLT2 inhibitors are the topics discussed by John Mandrola, MD in this week ’ s podcasttheheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 9, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Empagliflozin's HFrEF Benefit Steady With Sacubitril/Valsartan Empagliflozin's HFrEF Benefit Steady With Sacubitril/Valsartan
The SGLT2 inhibitor empagliflozin works just as well when added on top of a second major agent used to treat patients with heart failure and reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 7, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

AHA Statement Highlights Cardiorenal Benefit of Diabetes Drugs AHA Statement Highlights Cardiorenal Benefit of Diabetes Drugs
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against heart disease and kidney disease progression, the AHA says.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 28, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

SGLT2 Inhibitors May Lower the Risk of Major Cardiovascular Events SGLT2 Inhibitors May Lower the Risk of Major Cardiovascular Events
SGLT2 inhibitors may lower the risk of major cardiovascular events in people with type 2 diabetes more effectively than DPP-4 inhibitors , a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 28, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

DAPA-CKD Resets eGFR Floor for Safe SGLT2 Inhibitor Use DAPA-CKD Resets eGFR Floor for Safe SGLT2 Inhibitor Use
‘ It's time to reduce the eGFR level for initiating an SGLT2 inhibitor to as low as 25, ’ suggests an expert.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 26, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

VERTIS CV: Ertugliflozin Benefit Falls Short of Other SGLT2 Inhibitors VERTIS CV: Ertugliflozin Benefit Falls Short of Other SGLT2 Inhibitors
Analyses from the trial of the sodium-glucose transporter 2 inhibitor ertugliflozin in patients with type 2 diabetes helped better define positive effects the drug had on renal function.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 25, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Major Adverse CV Event Risk Reduced With SGLT2 Inhibitors
THURSDAY, Sept. 24, 2020 -- For individuals with type 2 diabetes, sodium glucose cotransporter 2 (SGLT2) inhibitors are associated with a reduced risk for cardiovascular events during short-term follow-up, according to a study published online Sept.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 24, 2020 Category: Pharmaceuticals Source Type: news

Novel Type 2 Diabetes Drugs Incur High Costs in Medicare Novel Type 2 Diabetes Drugs Incur High Costs in Medicare
In Medicare Part D, beneficiaries pay 3 to 8 times more out of pocket for SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors than for older glucose-lowering agents.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 21, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Type 2 Diabetes Drugs and Their Use Are Top of EASD Agenda Type 2 Diabetes Drugs and Their Use Are Top of EASD Agenda
The virtual 2020 meeting of the European Association for the Study of Diabetes will feature new data and insights on SGLT2 inhibitors and GLP-1 receptor agonists, technology, COVID-19, and much more.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 16, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

DAPA-CKD: SGLT2 Inhibitors'The Beta-Blockers for the Kidneys'DAPA-CKD: SGLT2 Inhibitors'The Beta-Blockers for the Kidneys '
Nephrologists Jennie Lin and Leslie Gewin discuss the effects of dapagliflozin in patients with CKD. How do the DAPA-CKD findings fit with the CREDENCE data on SGLT2 inhibitors?Medscape Nephrology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 4, 2020 Category: Intensive Care Tags: Nephrology Commentary Source Type: news

SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context
Dr Ileana Pi ñ a asks the lead investigator how his trial on empagliflozin in HFrEF compares with DAPA-HF. They speculate on the likely mechanism of action of these relatively new drugs.theheart.org on Medscape (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 1, 2020 Category: Intensive Care Tags: Cardiology Commentary Source Type: news

SGLT2 inhibitors can slow progression of chronic kidney disease
(ERA-EDTA) The CREDENCE trial [3] provided evidence that the SGLT2 inhibitor Canagliflozin slows the progression of CKD in individuals with type 2 diabetes (T2D) and CKD with albuminuria. The Phase III DAPA-CKD trial [1] has now shown that the SGLT2 inhibitor Dapagliflozin can significantly slow CKD progression in all CKD patients, not only in those with diabetes. This breakthrough in kidney disease treatment goes back to an incidental study finding of Professor Christoph Wanner, President of the ERA-EDTA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 31, 2020 Category: International Medicine & Public Health Source Type: news

DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes
DAPA-CKD showed that dapagliflozin helped patients with albuminuria and declining eGFR, whether or not they also had type 2 diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 30, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

SGLT2 Inhibitors With Metformin Do Not Up Fracture Risk SGLT2 Inhibitors With Metformin Do Not Up Fracture Risk
The combination of SGLT-2 inhibitors and metformin is not associated with an increase in fracture risk among patients with type 2 diabetes, according to a meta-analysis of 25 randomized, controlled trials.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 21, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors Have a Breakout Year SGLT2 Inhibitors Have a Breakout Year
First indicated for type 2 diabetes, the benefits proven during the past year have thrust the drug class into the top tier of potential treatments for cardiac and renal disease.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 7, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Unexpected Rosuvastatin-Canagliflozin Adverse Effect Reported Unexpected Rosuvastatin-Canagliflozin Adverse Effect Reported
Canadian clinicians report the rare case of a 76-year-old woman who had a sharp spike in plasma levels of rosuvastatin within days of starting the SGLT2 inhibitor.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 5, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Positive Top-line Results for Another SGLT2 Inhibitor in HF Positive Top-line Results for Another SGLT2 Inhibitor in HF
Empagliflozin reduced the risk of CV death or heart failure hospitalization in a phase 3 trial of adults with HF and reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 31, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

SGLT2 Inhibitors Commonly Used for Diabetes Linked to Higher Odds for a Serious Complication
TUESDAY, July 28, 2020 -- People taking a class of diabetes medications called SGLT2s have up to three times the risk for a serious complication called diabetic ketoacidosis (DKA) compared to people taking another drug, new research reveals. SGLT2... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 28, 2020 Category: General Medicine Source Type: news

Real-World Data Show SGLT2 Inhibitors for Diabetes Triple DKA Risk Real-World Data Show SGLT2 Inhibitors for Diabetes Triple DKA Risk
Finding appears to be a class effect; drugs are also increasingly being used by cardiologists and nephrologists, so it's important they know about this rare but serious side effect.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 27, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors Now'Belong to Cardiologists and Nephrologists'SGLT2 Inhibitors Now'Belong to Cardiologists and Nephrologists '
Physicians of different specialties are still getting used to the idea that SGLT2 inhibitors aren't just for diabetes anymore.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 17, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

SGLT2is Beyond Diabetes: A Team Effort in CVD and Renal Disease SGLT2is Beyond Diabetes: A Team Effort in CVD and Renal Disease
As use of SGLT2 inhibitors expands, treatment of patients with diabetes, heart failure, and cardiovascular and renal disease requires close collaboration among specialists and primary care providers.American College of Cardiology & Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 16, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news

VERTIS-CV Results'Disappoint,' Raise More Questions VERTIS-CV Results'Disappoint,' Raise More Questions
The VERTIS-CV trial results presented at the ADA meeting raise more questions about the benefits of SGLT2 inhibitors than they answer, says Dr Harpreet Bajaj.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Dapagliflozin's Renal Protection Extends to'Fast Decline' of eGFR Dapagliflozin's Renal Protection Extends to'Fast Decline' of eGFR
Treatment of patients with type 2 diabetes with the SGLT2 inhibitor led to a significant drop in the occurrence of'fast decline'of renal function in DECLARE-TIMI 58, the drug's main cardiovascular outcome trial.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 25, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

BEST: Bexagliflozin CV Outcomes Trial Meets Objectives BEST: Bexagliflozin CV Outcomes Trial Meets Objectives
Topline results of a cardiovascular outcomes trial of the investigational SGLT2 inhibitor for type 2 diabetes were presented at the ADA meeting and will be part of a new drug application to the US FDA.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 24, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

VERTIS-CV: Late-Comer Ertugliflozin Shows HF Benefit Only in CVOT VERTIS-CV: Late-Comer Ertugliflozin Shows HF Benefit Only in CVOT
The findings are consistent with previous cardiovascular outcome trials of other SGLT2 inhibitors in type 2 diabetes, says an expert.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 18, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

GLP-1 Receptor Agonists vs SGLT2 Inhibitors for T2DM GLP-1 Receptor Agonists vs SGLT2 Inhibitors for T2DM
How do these treatments for type 2 diabetes compare in terms of cardiovascular and renal outcomes and risk for adverse events?Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Those Most in Need Least Likely to Get Newer Diabetes Medications Those Most in Need Least Likely to Get Newer Diabetes Medications
Racial and socioeconomic disparities may be impeding access to newer diabetes medications, including DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors, among US patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes
The SGLT2 inhibitor reduced the need to start insulin treatment or intensify existing insulin treatment compared with placebo in a post-hoc analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors vs GLP-1 Agonists for Diabetes in Real-World Study SGLT2 Inhibitors vs GLP-1 Agonists for Diabetes in Real-World Study
Compared with GLP-1 agonists, SGLT2 inhibitors were linked with similar cardiovascular outcomes but less heart failure, treatment discontinuation, healthcare use, and cost in a new study.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 14, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Dapagliflozin Benefits in HF Regardless of Diuretics: DAPA-HF Dapagliflozin Benefits in HF Regardless of Diuretics: DAPA-HF
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early speculation, diuresis may be off the list.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 10, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

EU Green Light for Canagliflozin to Slow Diabetic Kidney Disease EU Green Light for Canagliflozin to Slow Diabetic Kidney Disease
The CHMP has recommended approval for the SGLT2 inhibitor canagliflozin (Invokana) be extended to include diabetic kidney disease.International Approvals (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 1, 2020 Category: Transplant Surgery Tags: Diabetes & Endocrinology News Alert Source Type: news

Type 2 Diabetes Update: Semaglutide and Linagliptin as Basal Insulin Alternatives
Cardiovascular comorbidities and risk reduction play a major new role in pharmacologic therapy for type 2 diabetes, with sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists now recommended as part of the glucose-lowering regimen for patients who have established atherosclerotic cardiovascular disease (ASCVD) or indicators of high-risk, chronic kidney disease (CKD) or heart failure (HF). (Source: Caring for the Ages)
Source: Caring for the Ages - May 31, 2020 Category: Health Management Authors: Christine Kilgore Source Type: news

DCRI-collaboration-empact-mi
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin ’s effects following an acute myocardial infarction Ischemic heart disease, including myocardial infarction, is the leading cause of death in the world1EMPACT-MI is the first trial in the SGLT2 inhibitor class to investigate the prevention of heart failure after acute myocardial infarction in adults with and without diabetesThe trial is part of the EMPOWER clinical trial program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the li...
Source: Boehringer Ingelheim Corporate News - May 26, 2020 Category: Research Source Type: news

Call for More Transparency in Gray Area of Post-Approval Drug Studies Call for More Transparency in Gray Area of Post-Approval Drug Studies
' Post-market safety studies are often inadequate, not completed, and poorly reported in the public arena,'say the authors of study examining SGLT2 inhibitors. But clinicians say this is not so black and white.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 6, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors May Prevent Diabetic Kidney Disease SGLT2 Inhibitors May Prevent Diabetic Kidney Disease
Patients with type 2 diabetes in real-world practice who received an SGLT2 inhibitor rather than a DPP-4 inhibitor were less likely to develop serious renal events, consistent with clinical trial findings.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 4, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors Linked to Reduced Risk for Serious Renal Events
FRIDAY, May 1, 2020 -- Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a reduced risk for serious renal events compared with dipeptidyl peptidase-4 inhibitors, according to a study published online April 29 in The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2020 Category: Pharmaceuticals Source Type: news